TMSP(SH:600671)2025-04-27 08:00Financial Performance - The company's operating revenue for Q1 2025 was CNY 52,293,464.92, an increase of 88.55% compared to CNY 27,735,233.63 in the same period last year[4]. - Net profit attributable to shareholders was CNY 5,094,308.04, a significant recovery from a loss of CNY 9,722,783.48 in the previous year[4]. - Basic and diluted earnings per share were both CNY 0.0418, compared to a loss of CNY 0.0798 per share in the same period last year[4]. - Operating profit for Q1 2025 was ¥3,215,303.05, compared to an operating loss of ¥10,916,187.17 in the same period last year[21]. - Net profit for Q1 2025 was ¥2,910,762.90, a recovery from a net loss of ¥10,098,459.85 in Q1 2024[21]. Cash Flow and Assets - Cash flow from operating activities was negative at CNY -9,652,306.07, worsening from CNY -3,573,723.68 in the previous year[4]. - Cash flow from operating activities in Q1 2025 showed a net outflow of ¥9,652,306.07, worsening from a net outflow of ¥3,573,723.68 in Q1 2024[24]. - The company's cash and cash equivalents decreased to RMB 33,246,867.03 from RMB 65,724,985.87, a decline of approximately 49.5%[16]. - Cash and cash equivalents at the end of Q1 2025 were ¥24,255,029.38, down from ¥55,920,693.46 at the end of Q1 2024[24]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 430,219,519.16, a decrease of 2.55% from CNY 441,463,237.69 at the end of the previous year[5]. - The company's current assets totaled RMB 217,008,513.62, slightly down from RMB 222,713,693.72 at the end of 2024, indicating a decrease of about 2.99%[17]. - The company's total liabilities were RMB 342,259,854.95, down from RMB 356,444,336.38, showing a reduction of about 3.97%[18]. - The company's total equity attributable to shareholders increased to RMB 57,478,192.84 from RMB 52,383,884.80, marking an increase of approximately 9.4%[19]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,805[10]. - Shareholder Source Medical plans to increase its stake in the company by investing between RMB 10 million and RMB 20 million over a six-month period starting August 24, 2024[13]. - As of February 19, 2025, Source Medical had acquired a total of 1,114,100 shares, representing 0.91% of the company's total share capital, for a total investment of RMB 1,002.69 million[13]. Revenue and Sales - The company's revenue growth was driven by increases in sales from subsidiaries, contributing an additional CNY 11,300,000, CNY 5,160,000, CNY 2,520,000, and CNY 2,420,000 respectively[9]. - The company reported a significant increase in sales revenue from services, with cash received from sales reaching ¥43,618,766.57 in Q1 2025, up from ¥37,294,343.10 in Q1 2024[23]. Accounting and Reporting - The company plans to implement new accounting standards starting in 2025, which may affect future financial reporting[25].